Regulation of Oxidative Stress by Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Mediated by PACAP Receptor

被引:0
作者
Hirokazu Ohtaki
Atsushi Satoh
Tomoya Nakamachi
Sachiko Yofu
Kenji Dohi
Hiroyoshi Mori
Kenji Ohara
Kazuyuki Miyamoto
Hitoshi Hashimoto
Norihito Shintani
Akemichi Baba
Masaji Matsunaga
Seiji Shioda
机构
[1] Showa University School of Medicine,Department of Anatomy
[2] Gene Trophology Research Institute,Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences
[3] Osaka University,undefined
来源
Journal of Molecular Neuroscience | 2010年 / 42卷
关键词
PACAP; PACAP-specific receptor (PAC1R); Oxidative stress; Aging;
D O I
暂无
中图分类号
学科分类号
摘要
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a multifunctional peptide that has been shown to be neuroprotective following a diverse range of cell injuries. Although several mechanisms regulating this effect have been reported, no direct evidence has linked PACAP to the regulation of oxidative stress, despite the fact that oxidative stress is a factor in the injury progression that occurs in most models. In the present study, we investigated the plasma oxidative metabolite and anti-oxidation potential levels of PACAP-deficient mice, as well as those of wild-type animals treated with PACAP38. These were assayed by the determination of Reactive Oxidative Metabolites (d-ROMs) and the Biological Anti-oxidant Potential (BAP) using the Free Radical Electron Evaluator system. We also investigated the direct radical scavenging potency of PACAP38 and the functional role of its receptor in the regulation of oxidative stress by PACAP, by using vasoactive intestinal peptide (VIP) and the PACAP receptor antagonist, PACAP6–38. Although younger PACAP null mice displayed no significant effect, greater d-ROMs and lower BAP values were recorded in older animals than in their wild-type littermates. Intravenous injection of PACAP38 in wild-type mice decreased the plasma d-ROMs and BAP values in a dose-dependent manner. These effects were not reproduced using VIP and were abolished by co-treatment with PACAP38 and the PAC1R antagonist PACAP6-38. Taken together, these results suggest that PACAP plays an important role in the physiological regulation of oxidative stress.
引用
收藏
页码:397 / 403
页数:6
相关论文
共 124 条
[1]  
Abad C(2002)Pituitary adenylate-cyclase-activating polypeptide expression in the immune system Neuroimmunomodulation 10 177-186
[2]  
Martinez C(1998)Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems Jpn J Physiol 48 301-331
[3]  
Leceta J(2005)Potential protective action of pituitary adenylate cyclase-activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury Blood 107 661-668
[4]  
Juarranz MG(2009)Presence of pituitary adenylate cyclase activating polypeptide-38 in human plasma and milk Eur J Endocrinol 160 561-565
[5]  
Delgado M(2008)Peroxiredoxin 2 is involved in the neuroprotective effects of PACAP in cultured cerebellar granule neurons J Mol Neurosci 36 61-72
[6]  
Gomariz RP(2009)The senescence-accelerated mouse (SAM): a higher oxidative stress and age-dependent degenerative diseases model Neurochem Res 34 679-687
[7]  
Arimura A(2001)Inhibition of endotoxin-induced macrophage chemokine production by VIP and PACAP in vitro and in vivo Arch Physiol Biochem 109 377-382
[8]  
Arimura A(1999)Manganese superoxide dismutase mediates the early release of mitochondrial cytochrome c and subsequent DNA fragmentation after permanent focal cerebral ischemia in mice J Neurosci 19 3414-3422
[9]  
Li M(2002)Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity Crit Rev Oral Biol Med 13 229-237
[10]  
Batuman V(2006)Pituitary adenylate cyclase activating polypeptide protects cardiomyocytes against oxidative stress-induced apoptosis Peptides 27 87-94